GlassScriptPhysician profile
Amber D Van Laar
NPI 1023246840
$412,673.09
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2021: $37.02 · 2022: $49K · 2023: $194K · 2024: $169K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $363K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $362,872.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Asklepios Biopharmaceutical INC. | $362,872.90 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $49,486.70 | 2022 | |
| Acadia Pharmaceuticals INC | $243.23 | 2019 | |
| Boston Scientific Corporation | $37.02 | 2021 | |
| Abbvie INC. | $33.24 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Van Laar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.